Are you still bullish on Genmab AS?
|By Ellen Johnson|
hype ideas genmab as healthcare biotechnology
We will cover Genmab AS in this post. What is Genmab AS Target Price Odds to finish over Current Price? Based on normal probability distribution, the odds of Genmab AS to move above current price in 30 days from now is under 4%. The Genmab AS probability density function shows the probability of Genmab AS Stock to fall within a particular range of prices over 30 days . Assuming 30 trading days horizon, Genmab AS has beta of 0.1316 . This indicates as returns on market go up, Genmab AS average returns are expected to increase less than the benchmark. However during bear market, the loss on holding Genmab AS will be expected to be much smaller as well. Additionally Genmab AS has an alpha of 0.388 implying that it can potentially generate 0.388% excess return over S&P 500 after adjusting for the inherited market risk (beta). Genmab AS dividends can provide a clue to current valuation of the stock. Genmab AS is not expected to issue dividends this year as it trying to preserve or re-invest any of the funds available for distribution to stakeholders.
On a scale of 0 to 100 Genmab AS holds performance score of 12. The company retains Market Volatility (i.e. Beta) of 0.1316 which attests that as returns on market increase, Genmab AS returns are expected to increase less than the market. However during bear market, the loss on holding Genmab AS will be expected to be smaller as well. . Although it is vital to follow to Genmab AS current price history, it is good to be conservative about what you can actually do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By evaluating Genmab AS technical indicators you can presently evaluate if the expected return of 0.4237% will be sustainable into the future. Please utilizes Genmab AS Coefficient Of Variation, Maximum Drawdown as well as the relationship between Maximum Drawdown and Skewness to make a quick decision on weather Genmab AS current trending patterns will revert.
This company currently falls under 'Large-Cap' category with current market capitalization of 10.91B. Genmab AS retains Downside Deviation of 2.25, Market Risk Adjusted Performance of 2.78 and Risk Adjusted Performance of 0.3075. The latest price spikes of Genmab AS may raise some interest from investors. The Stock closed today at a share price of 16.85 on 75300.000 in trading volume. The company directors and management were quite successful positioning the corporation components to exploit market volatility in February 2019. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.3127. The current volatility is consistent with the ongoing market swings in December 2018 as well as with Genmab AS unsystematic, company specific events. Genmab AS makes 61.49m shares outstanding. Genmab AS is selling for 17.01. This is 1.10 percent increase. Today lowest is 16.85.
Genmab AS Current Market Performance
|Genmab AS Shares Rating Lowered by Zacks Investment Research...||11/26/2018|
|Lafayette Investments Has Increased Abbvie Com Stake ISS ORD...||12/13/2018|
|How Did Genmab ASs 20 percent ROE Fare Against The Industry ...||12/21/2018|
|Analyzing Hot Movers Genmab AS - Stock Digest||01/04/2019|
|Genmab AS Rating Increased to Strong-Buy at Zacks Investment...||01/16/2019|
|Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile|
|This headline from Macroaxis disseminated on 01/11/2019 added to the next day price reduction.The overall trading delta to closing price of the next trading day was 1.74% . The overall trading delta when the story was published to current closing price is 3.43% .|
Similar stores for Genmab AS
Genmab AS Rating Increased to Strong-Buy at Zacks Investment Research Fairfield CurrentGenmab AS was upgraded by Zacks Investment Research from a hold rating to a strong-buy rating in a note issued to investors on ...
United American Securities Decreased Its Johnson Johnson Com Holding as Share Price Rose Jupiter Asset Management LTD Boosted Msci Holding by 908,364 The FinReviewerUnited American Securities Inc decreased its stake in Johnson Johnson Com by 4.92 percent based on its latest 2018Q3 regulatory filing with the SEC. United ...
Genmab AS is currently under evaluation in price to earning category among related companies. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investor monitor on a daily basis. Holding a low PE stock is less risky because. When a company's profitability fall, it is likely that earnings will also go down..In other words, if you start from a lower position your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.